These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 33335563)
21. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. Huang Y; Huang C; Zhang Q; Shen T; Sun J BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487 [TBL] [Abstract][Full Text] [Related]
22. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease. Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105 [TBL] [Abstract][Full Text] [Related]
24. Neurofilament light as a biomarker for motor decline in Parkinson's disease. Liu Y; Dou K; Xue L; Li X; Xie A Front Neurosci; 2022; 16():959261. PubMed ID: 36117629 [TBL] [Abstract][Full Text] [Related]
26. Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. Gibson LL; Pollak TA; Heslegrave A; Hye A; Batzu L; Rota S; Trivedi D; Nicholson TR; Ffytche D; Zetterberg H; Chaudhuri KR; Aarsland D J Parkinsons Dis; 2022; 12(5):1527-1538. PubMed ID: 35466956 [TBL] [Abstract][Full Text] [Related]
27. Increased CSF NFL in Non-demented Parkinson's Disease Subjects Reflects Early White Matter Damage. Papuć E; Rejdak K Front Aging Neurosci; 2020; 12():128. PubMed ID: 32477099 [TBL] [Abstract][Full Text] [Related]
28. Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients. Fiorillo A; Gallego JJ; Casanova-Ferrer F; Urios A; Ballester MP; San Miguel T; Megías J; Kosenko E; Tosca J; Rios MP; Escudero-García D; Montoliu C Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834174 [TBL] [Abstract][Full Text] [Related]
29. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610 [TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis. Hu X; Yang Y; Gong D Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490 [TBL] [Abstract][Full Text] [Related]
31. Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson's disease: a follow-up study. Chan L; Chung CC; Hsieh YC; Wu RM; Hong CT Ther Adv Neurol Disord; 2023; 16():17562864221150329. PubMed ID: 36741351 [TBL] [Abstract][Full Text] [Related]
32. The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study. Wang X; Yang X; He W; Song X; Zhang G; Niu P; Chen T J Affect Disord; 2023 Dec; 343():144-152. PubMed ID: 37805158 [TBL] [Abstract][Full Text] [Related]
33. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869 [TBL] [Abstract][Full Text] [Related]
34. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease. Batzu L; Rota S; Hye A; Heslegrave A; Trivedi D; Gibson LL; Farrell C; Zinzalias P; Rizos A; Zetterberg H; Chaudhuri KR; Aarsland D NPJ Parkinsons Dis; 2022 Nov; 8(1):154. PubMed ID: 36371469 [TBL] [Abstract][Full Text] [Related]
35. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease. Yang D; Xie H; Wu S; Ying C; Chen Y; Ge Y; Yao R; Li K; Jiang Z; Chen G NPJ Parkinsons Dis; 2023 Sep; 9(1):132. PubMed ID: 37699957 [TBL] [Abstract][Full Text] [Related]
36. Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease. Yin W; Zhu Y; Yang B; Wang F; Yin K; Zhou C; Ren H; Yang X Neurol Sci; 2022 Apr; 43(4):2839-2843. PubMed ID: 35088243 [TBL] [Abstract][Full Text] [Related]
37. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories. Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500 [TBL] [Abstract][Full Text] [Related]
38. Blood neurofilament light chain in Parkinson's disease. Buhmann C; Magnus T; Choe CU J Neural Transm (Vienna); 2023 Jun; 130(6):755-762. PubMed ID: 37067597 [TBL] [Abstract][Full Text] [Related]
39. Association of Neurofilament Light With the Development and Severity of Parkinson Disease. Halloway S; Desai P; Beck T; Aggarwal N; Agarwal P; Evans D; Rajan KB; Neurology; 2022 May; 98(22):e2185-e2193. PubMed ID: 35418452 [TBL] [Abstract][Full Text] [Related]
40. Urinary extracellular vesicle dynamics in Parkinson's disease patients with urinary dysfunction. Roy S; Kashyap NN; Anchan AS; Punja D; Jasti DB; Upadhya D Front Neurol; 2023; 14():1250832. PubMed ID: 38046591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]